On behalf of a major securities exchange, developed estimate of economic damages arising from alleged infringement of patented technology relating to an automated exchange for trading derivative securities, such as options contracts, and a process for trading a financial instrument on an automated exchange. Technology addressed pro-rata matching, public customer priority, professional participation, small-order preference and away-market protection.
Life Sciences Litigation Insights: April 2022
CRA’s Life Sciences Litigation team provides periodic summaries of notable developments in litigation. In this issue, we share notable cases from 2021 and...